Anti-thymocyte globulin (ATG) is an infusion of horse or rabbit-derived antibodies against human T cells, which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia.

Two antithymocyte globulin (ATG) agents licensed for clinical use in the United States are Thymoglobulin (rabbit ATG, rATG, Genzyme) and Atgam (equine ATG, eATG, Pfizer). Thymoglobulin and Atgam are currently licensed for use in the treatment of renal allograft rejection; Atgam is additionally licensed for use in the treatment of aplastic anemia. Both drugs are used in off-label applications, especially as immunosuppression induction agents before and/or during kidney transplantation.... Wikipedia

 

 

Manufacturer's Website: Not Available                                                                                                     Average retail cost: $11,400/vial

 

 

 

Search Terms:ATGAM, Lymphocyte Immune Globulin, Antithymocyte Globulin (Equine), renal allograft rejection, organ transplantation, aplastic anemia, immunosuppression